2014

BioAlliance Pharma strengthens its financial resources with the support of its top shareholder

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the setup of a €10 million loan granted by its top shareholder, Financière de la Montagne. A BioAlliance Pharma shareholder since 2008, today its top shareholder and member of its Board of Directors, Financière de la Montagne thus…read more →

FDA approval of Beleodaq™ (belinostat)

• Accelerated Approval of Topotarget’s Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma • Early Action follows Priority Review 5 weeks before PDUFA Date • Trigger milestone payment of USD 25 million to Topotarget • Beleodaq™ is expected to be available to patients in July 2014 and will be launched through Spectrum Pharmaceutical’s existing oncology…read more →

BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, and Topotarget A/S (NASDAQ OMX – TOPO), a Danish based biopharmaceutical company focusing on late-stage clinical development for orphan oncology, today announce that the shareholders of both companies have approved all resolutions with more than 99% voting in favor of…read more →

Execution of a license agreement with EMS for Sitavig® in Brazil

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the signature of a license agreement for Sitavig® (acyclovir Lauriad®) with EMS S/A for commercialization rights in Brazil. Approved in the treatment of recurrent labial herpes, Sitavig® is already registered in the United States and in 10 major…read more →

Merger Plan with Topotarget: Pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, today announces that it has received a pre-approval from NASDAQ OMX Copenhagen for the secondary listing and admission to trading on NASDAQ OMX Copenhagen of the shares of BioAlliance Pharma SA, subject to completion of the merger of Topotarget and…read more →

BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the issuance of a new patent in Japan strengthening the industrial property protection of Livatag® (doxorubicin Transdrug™), currently being developed in primary liver cancer. Livatag® was already patented until 2019 with a first patent family covering the pharmaceutical…read more →

Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced announces today that on 26 May 2014, the Autorité des Marchés Financiers has registered the « Document E » (n° E.14-034) and granted clearance on the “Prospectus d’admission” (n° 14-232) related to the proposed cross-border merger of Topotarget…read more →

Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo

THE ORPHAN ONCOLOGY INNOVATOR  DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO  – Onxeo expected to have a broader complementary pipeline of late-stage products addressing significant unmet medical needs – – Topotarget shareholders will receive 2 new BioAlliance Pharma ordinary shares for every 27 Topotarget shares that they own, which implies approximately a 1/3…read more →

Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that Livatag® (doxorubicin Transdrug™) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (primary liver cancer) after treatment with Sorafenib. The Fast Track procedure is designed to facilitate interactions…read more →

BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the completion of enrollment in the Phase II clinical trial with Validive® (clonidine Lauriad®) in the prevention and treatment of severe oral mucositis induced by radiotherapy and/or chemotherapy in head and neck cancer patients. This large and robust…read more →

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today published a summary of the key events of the first quarter of 2014, as well as its consolidated revenues for the quarter. Key orphan oncology programs Validive® and Livatag® have successfully reached important milestones during the first quarter of…read more →

BioAlliance Pharma Publishes its first Shareholder Newsletter

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces the publication of its first Shareholder Newsletter (1). This Newsletter completes BioAlliance Pharma’s communication with all of its shareholders, in addition to its website, its press releases and its participation in the financial community events. This first issue…read more →

BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company

– Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical needs – – Topotarget shareholders will receive 2 new BioAlliance Pharma ordinary shares for every 27 Topotarget shares that they own, which implies approximately a 1/3 ownership for Topotarget shareholders and approximately a 2/3 ownership for BioAlliance Pharma shareholders –…read more →

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety profile of the ReLive Phase III trial, today held its fourth meeting and once more unanimously recommended continuing the study…read more →

Publication of the 2013 Registration Document

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that its 2013 Registration Document, has been registered with the French Market Authorities (Autorité des Marchés Financiers) on April 7, 2014. The Registration Document is available to the public free of charge upon request as per current legal…read more →